NecstGen’s Post

Cell & gene therapies: How can market growth be sustained to maximise on opportunities? In this webinar, hosted by DDW and sponsored by Astrea Bioseparations, you will learn about how market growth can be sustained to maximise on opportunities in cell and gene therapy (CGT). You will hear from Doug Danison, Head of Commercial Strategy and Operations for Bayer CGT, Mark Treherne, Commercial Research Scientist and Chairperson at Spliceor, as well as Ian Scanlon, DSP Lead ATMP Purification at Astrea Bioseparations. Doug Danison will discuss transitioning innovative science into commercial success in the areas of CGTs. Mark Treherne will talk about advanced therapies and the development of RNA gene therapy for aggressive cancers which is being carried out at Spliceor. Ian Scanlon will discuss bottlenecks in advanced therapeutic delivery and how novel technologies can improve patient access and deliver sustainable processes. What you will learn: • Global opportunities created by advanced therapies in drug discovery • How sustainable growth is in this area and what the research sector should be focussing on for future success • The challenges this sector faces • Key trends for this sector. An audience Q&A session with the presenters will follow the webinar presentation.   Wed, Feb 28, 2024 3:00 PM - 4:00 PM GMT Register for this webinar and get your certificate of attendance! https://lnkd.in/eN-AKj-Y #CellandGeneTherapy #CGT #DrugDiscovery

Cell & gene therapies: How can market growth be sustained to maximise on opportunities? In this webinar, hosted by DDW and sponsored by Astrea Bioseparations, you will learn about how market growth can be sustained to maximise on opportunities in cell and gene therapy (CGT). You will hear from Doug Danison, Head of Commercial Strategy and Operations for Bayer CGT, Mark Treherne, Commercial Research Scientist and Chairperson at Spliceor, as well as Ian Scanlon, DSP Lead ATMP Purification at Astrea Bioseparations. Doug Danison will discuss transitioning innovative science into commercial success in the areas of CGTs. Mark Treherne will talk about advanced therapies and the development of RNA gene therapy for aggressive cancers which is being carried out at Spliceor. Ian Scanlon will discuss bottlenecks in advanced therapeutic delivery and how novel technologies can improve patient access and deliver sustainable processes. What you will learn: • Global opportunities created by advanced therapies in drug discovery • How sustainable growth is in this area and what the research sector should be focussing on for future success • The challenges this sector faces • Key trends for this sector. An audience Q&A session with the presenters will follow the webinar presentation.   Wed, Feb 28, 2024 3:00 PM - 4:00 PM GMT To secure your place, register for FREE now. https://lnkd.in/gjh7wdYm Sponsored by Astrea Bioseparations  #DrugDiscovery #AdvancedTherapies #CellandGeneTherapy

When Astrea Bioseparations expert Ian Scanlon speaks about how market growth (in Cell and Gene Therapy) can be sustained, you should listen! Learn how Ian and Astrea Bioseparations are supporting the growth of next generation therapies! #Astrea #CellAndGeneTherapy #IndustryExpert #BeTheBest

Cell & gene therapies: How can market growth be sustained to maximise on opportunities? In this webinar, hosted by DDW and sponsored by Astrea Bioseparations, you will learn about how market growth can be sustained to maximise on opportunities in cell and gene therapy (CGT). You will hear from Doug Danison, Head of Commercial Strategy and Operations for Bayer CGT, Mark Treherne, Commercial Research Scientist and Chairperson at Spliceor, as well as Ian Scanlon, DSP Lead ATMP Purification at Astrea Bioseparations. Doug Danison will discuss transitioning innovative science into commercial success in the areas of CGTs. Mark Treherne will talk about advanced therapies and the development of RNA gene therapy for aggressive cancers which is being carried out at Spliceor. Ian Scanlon will discuss bottlenecks in advanced therapeutic delivery and how novel technologies can improve patient access and deliver sustainable processes. What you will learn: • Global opportunities created by advanced therapies in drug discovery • How sustainable growth is in this area and what the research sector should be focussing on for future success • The challenges this sector faces • Key trends for this sector. An audience Q&A session with the presenters will follow the webinar presentation.   Wed, Feb 28, 2024 3:00 PM - 4:00 PM GMT To secure your place, register for FREE now. https://lnkd.in/gjh7wdYm #CellandGeneTherapy #AdvancedTherapies #DrugDiscovery

Only a few days left to register for this webinar! Cell & gene therapies: How can market growth be sustained to maximise on opportunities? In this webinar, hosted by DDW and sponsored by Astrea Bioseparations, you will learn about how market growth can be sustained to maximise on opportunities in cell and gene therapy (CGT). You will hear from Doug Danison, Head of Commercial Strategy and Operations for Bayer CGT, Mark Treherne, Commercial Research Scientist and Chairperson at Spliceor, as well as Ian Scanlon, DSP Lead ATMP Purification at Astrea Bioseparations. Doug Danison will discuss transitioning innovative science into commercial success in the areas of CGTs. Mark Treherne will talk about advanced therapies and the development of RNA gene therapy for aggressive cancers which is being carried out at Spliceor. Ian Scanlon will discuss bottlenecks in advanced therapeutic delivery and how novel technologies can improve patient access and deliver sustainable processes. What you will learn: • Global opportunities created by advanced therapies in drug discovery • How sustainable growth is in this area and what the research sector should be focussing on for future success • The challenges this sector faces • Key trends for this sector. An audience Q&A session with the presenters will follow the webinar presentation.   Wed, Feb 28, 2024 3:00 PM - 4:00 PM GMT To secure your place, register for FREE now. https://lnkd.in/gjh7wdYm #CellandGeneTherapy #AdvancedTherapies #DrugDiscovery

With the FDA expecting to approve 10–20 Cell and Gene Therapies (CGTs) annually by 2025, it is evident that the field will continue to hold immense commercial and medical opportunities. To harness this potential, stakeholders across the CGT ecosystems must collaborate to overcome barriers to delivering life-changing treatment to patients.   Delivered through an interactive virtual platform, this event features over three hours of insightful sessions led by 6 speakers. The discussions will provide industry perspectives on essential success factors for developing CGTs, covering topics such as: 1. Large scale processing of mesenchymal stem cells (MSC) and T cell immunotherapies 2. Integrated, cutting-edge solutions and process advancements that supports end-to-end workflow 3. Regulatory considerations in raw material selection from research through commercialization 4. Analytical platforms to evaluate the quality, safety, and efficacy of cell-based products #freewebinar #cellgenetherapy https://2ly.link/1wu5O

Have you registered for tomorrow's webinar? Cell & gene therapies: How can market growth be sustained to maximise on opportunities? In this webinar, hosted by DDW and sponsored by Astrea Bioseparations, you will learn about how market growth can be sustained to maximise on opportunities in cell and gene therapy (CGT). You will hear from Doug Danison, Head of Commercial Strategy and Operations for Bayer CGT, Mark Treherne, Commercial Research Scientist and Chairperson at Spliceor, as well as Ian Scanlon, DSP Lead ATMP Purification at Astrea Bioseparations. Doug Danison will discuss transitioning innovative science into commercial success in the areas of CGTs. Mark Treherne will talk about advanced therapies and the development of RNA gene therapy for aggressive cancers which is being carried out at Spliceor. Ian Scanlon will discuss bottlenecks in advanced therapeutic delivery and how novel technologies can improve patient access and deliver sustainable processes. What you will learn: • Global opportunities created by advanced therapies in drug discovery • How sustainable growth is in this area and what the research sector should be focussing on for future success • The challenges this sector faces • Key trends for this sector. An audience Q&A session with the presenters will follow the webinar presentation.   Wed, Feb 28, 2024 3:00 PM - 4:00 PM GMT To secure your place for tomorrow's webinar, register for FREE now. https://lnkd.in/eN-AKj-Y #CellandGeneTherapy #AdvancedTherapies #DrugDiscovery

At the end of 2023, the first CRISPR-based gene therapy was approved by both the #MHRA and the #FDA: our AMSBIO #crispr expert, Dr Ifeanyi Enekwa, has written a blog to share some information, insights and thoughts for the future. https://lnkd.in/e6PiDuAi #CRISPRService #Blog #crisprcas9

Read the Spring issue of DDW now The Spring issue of Drug Discovery World (DDW) is out now. It looks at where we are in the fight against antimicrobial resistance, explores how structural biology is informing vaccine design, and offers advice on approaching dealmaking in biopharma. Other features in the Spring issue include: A market report on the drug discovery hotspots in Europe. A spotlight on the future potential of mRNA-based therapies. Analysis of the challenges and opportunities in cannabis research. Exclusive Cell & Gene Therapies Guide DDW has published the latest addition to its Guide Series, ‘Where is the global innovation in cell & gene therapy?‘ It covers the advancements taking place in cell and gene therapies and includes expert insight on current and future developments. Download to read about: Recent successes and the current state of the industry Predictions of what to expect going forward in the indusrry How to tailor CGT therapies for oncology and autoimmune disease Using gene therapy for age-related diseases Read the digital version here.  https://lnkd.in/e4P4ZbuK #DrugDiscovery #LifeSciences #DrugDevelopment

Andrew Way, who jointly heads up Jigsaw’s Life Science team, has published the next edition of his blog, which aims to provide any update on the Life Sciences sector and outline how we are helping our clients navigate this rapidly evolving landscape. In this “issue”, he explores the main challenges that are associated with the rising number of Cell & Gene Therapies entering the market and how these might be best tackled going forward. Read more here:  https://lnkd.in/e7EA3jN6 #mrx #lifescience